Neurodegenerative DiseasesAlzheimer's Disease, Lewy Body Dementia, and Traumatic Brain InjuryApoE4 is the strongest predictor of Alzheimer’s disease (AD); it is found in 60 percent of AD patients. Individuals with homozygous ApoE4 have a more than 20-fold increase in AD risk, and no treatment currently exists for ApoE4 AD. The lifetime risk of developing AD for those with homozygous ApoE4 is estimated to be 75 percent for women and 50 percent for men. The direct cost of AD to American society in 2015 was estimated to be more than $215 billion, and the cost is expected to grow to $1.2 trillion by 2050 (according to RAND, a nonprofit research organization).
ApoE4 AD is characterized by increase in P-tau and amyloidβ42, neuron-synapse loss in hippocampus region of the brain, and by cognitive decline. Artery has shown in multiple laboratory and mice models that manipulating ABCA1 functionality with our proprietary ABCA1 agonists has the potential to counteract ApoE4-drien AD with regard to both brain phenotype expression and cognition. The ability of our ABCA1 agonists to prevent ApoE4 AD in animals has been shown beyond doubt. Ongoing studies will tell if existing ApoE4 AD can indeed be reversed by Artery's medicines. This mechanism for counteracting ApoE4-driven pathogenesis will also apply to patients with Lewy Body Dementia, and traumatic brain injury, and it may potentially apply to patients with other neurological diseases.
In human-ApoE4 target-replacement mice studies, Artery's Cogpep™ has been shown to:
Prevent cognitive impairment
Decrease tau hyperphosphorylation
Decrease neuronal amyloidβ
Increase (VGLUT1) and neurogenesis
Increase ApoE receptor 2 (LRP8)
Artery has presented its scientific data orally and in poster abstracts, such as Society for Neuroscience, Alzheimer's Association International Conference, and Alzheimer’s Disease Parkinson’s Disease. Artery's first Alzheimer's disease peer-reviewed publication is now in print. The abstract can be found here!
Diabetes-generated Cardiovascular DiseaseThe primary funcations of Artery's Dipep™ are to stabilize atherosclerosis plaque, reduce atherosclerosis, and act against diabetes; all of these properties are found in one molecule. Dipep can be self-administered conveniently once weekly via subcutaneous injection.
Diabetes is becoming an epidemic worldwide, and 80 percent of Type 2 diabetes mellitus patients die from heart disease. The current diabetes medicines have marginal, if any, effects in preventing cardiovascular disease. In addition, approximately 15 percent of diabetes mellitus patients suffer a second heart disease event within 12 month of the first event. According to American Diabetes Association the direct medical cost of treating diabetes mellitus exceed $175 billion per year in the US.
Multiple mice models show that Dipep:
Improves glucose tolerance
Increased insulin secreting and enhances insulin sensitization
Is weight neutral
Preserves pancreas β-cell
Has quick onset of action